Isomorphic Labs secured $2.1 billion in a Series B funding round. Alphabet’s DeepMind spun out the London-based AI drug discovery company in 2021.
Thrive Capital led the investment. Alphabet, Abu Dhabi’s MGX, Singapore’s Temasek, and the UK Sovereign AI Fund also participated. This capital follows a $600 million funding round completed in 2025.
The company will use the funds to scale its proprietary AI drug design engine. Isomorphic Labs plans to expand its therapeutic program pipeline and global team.
The firm utilizes DeepMind’s AlphaFold protein structure prediction system to develop new medicines. The company maintains existing partnerships with major pharmaceutical firms.